NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Cell lines</td><td align="center">IC<sub>50</sub> (<i>μ</i>M)</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">MCF-7</td><td align="center">8.5</td></tr><tr><td align="left">C6</td><td align="center">8.7</td></tr><tr><td align="left">MDA-MB-231</td><td align="center">10.3</td></tr><tr><td align="left">Hs683</td><td align="center">12.7</td></tr><tr><td align="left">HT-29</td><td align="center">9.4</td></tr><tr><td align="left">DBTRG-05MG</td><td align="center">12.3</td></tr><tr><td align="left">Hs68 (normal cell line)</td><td align="center">25.0</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Inhibition of cancer cell lines by NBM-HD-1. Cells were incubated with NBM-HD-1 for 3 days. 

Evidence-Based Complementary and Alternative Medicine

tab1

Table 1

Table 1: NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity 